

## Doç. Dr. ZAFER ARIK

### Kişisel Bilgiler

İş Telefonu: [+90 312 305 2929](tel:+903123052929) Dahili: 2929

E-posta: [zafer.arik@hacettepe.edu.tr](mailto:zafer.arik@hacettepe.edu.tr)

Web: <https://avesis.hacettepe.edu.tr/zafer.arik>

### Uluslararası Araştırmacı ID'leri

Publons / Web Of Science ResearcherID: A-7499-2018

Yoksis Araştırmacı ID: 252911

### Eğitim Bilgileri

Tıpta Yandal Uzmanlık, Hacettepe Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı Medikal Onkoloji Bilim Dalı, Türkiye 2011 - 2013

Tıpta Uzmanlık, Hacettepe Üniversitesi, Tıp Fakültesi, İç Hastalıkları, Türkiye 2004 - 2010

Lisans, Hacettepe Üniversitesi, Tıp Fakültesi (İngilizce), Türkiye 1997 - 2004

### Yabancı Diller

İngilizce, B2 Orta Üstü

### Yaptığı Tezler

Tıpta Uzmanlık, HACETTEPE ÜNİVERSİTESİ HASTANELERİ'NDE TAKİP EDİLEN METASTATİK RENAL HÜCRELİ KANSER HASTALARININ SAĞKALIMLARININ ZAMAN İÇİNDE DEĞİŞİMİNİN İNCELENMESİ, Hacettepe Üniversitesi, Tıp Fakültesi, İç Hastalıkları Medikal Onkoloji, 2013

Tıpta Uzmanlık, ZOLEDRONİK ASİDİN RATLARDA DOKU SDF-1 EKSPRESYONU ÜZERİNDEKİ ETKİSİ, Hacettepe Üniversitesi, Tıp Fakültesi, İç Hastalıkları, 2010

### Araştırma Alanları

Tıp, Sağlık Bilimleri, Dahili Tıp Bilimleri, İç Hastalıkları, Onkoloji

### Akademik Unvanlar / Görevler

Doç. Dr., Hacettepe Üniversitesi, Tıp Fakültesi (Türkçe), Dahili Tıp Bilimleri Bölümü, 2017 - Devam Ediyor

### SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler

- Efficacy and safety of bevacizumab in patients with low-grade serous ovarian cancer**  
Karacin C., Sunar V., Urakci Z., YILMAZ A., Ayhan M., Ersoy M., Guven D. C., Erturk I., Durmus Y., Karacin P., et al.  
Future oncology (London, England), cilt.20, sa.4, ss.207-214, 2024 (SCI-Expanded)

- II. **Seven-Year Single-Center Experience of the Efficacy and Safety of Ferric Carboxymaltose in Cancer Patients with Iron-Deficiency Anemia**  
AKTAŞ B. Y., ATA E. B., ÇEŞMECİ E., ÇAKIR İ. Y., Coşkunpınar M., TAHILLIOĞLU Y., GÜNER G., GÜVEN D. C., ARIK Z., KERTMEN N., et al.  
Current Oncology, cilt.30, sa.11, ss.9689-9700, 2023 (SCI-Expanded)
- III. **KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer**  
KUŞ F., Guven D. C., YILDIRIM H. Ç., Chalabiyev E., AKYILDIZ A., Tatar O. D., ŞAHİN Y., Ileri S., Karaca E., KERTMEN N., et al.  
Biomarkers in Medicine, cilt.17, sa.7, ss.379-389, 2023 (SCI-Expanded)
- IV. **Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy**  
GÜVEN D. C., Incesu F. G. G., YILDIRIM H. Ç., Erul E., Chalabiyev E., AKTAŞ B. Y., YÜCE D., ARIK Z., KILIÇKAP S., AKSOY S., et al.  
INTERNATIONAL JOURNAL OF CANCER, cilt.152, ss.679-685, 2023 (SCI-Expanded)
- V. **Biochemical Response Evaluation on Lymphomas: Proposing a Scoring System**  
ERDAT E. C., ARIK Z., BARIŞTA İ.  
UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, cilt.33, sa.3, ss.170-178, 2023 (SCI-Expanded)
- VI. **Lesson learned from the pandemic: Isolation and hygiene measures for COVID-19 could reduce the nosocomial infection rates in oncology wards**  
GÜVEN D. C., EROĞLU İ., Ismayilov R., ULUSOYDAN E., AKTEPE O. H., TELLİ DİZMAN G., ARIK Z., DİZDAR Ö., ÜNAL S., METAN G., et al.  
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, cilt.28, sa.8, ss.1807-1811, 2022 (SCI-Expanded)
- VII. **Comparison of weekly methotrexate regimen versus methotrexate folinic acid 8-day regimen for treatment of low-risk gestational trophoblastic neoplasia**  
Korkmaz V., Sunar V., Akar S., Alinca C. M., ARIK Z., Boran N., Ozdal B., Ustun Y. E.  
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, cilt.18, sa.3, ss.326-332, 2022 (SCI-Expanded)
- VIII. **Frequency of germline BRCA1/2 mutations and association with clinicopathological characteristics in Turkish women with epithelial ovarian cancer**  
Sunar V., Korkmaz V., Topcu V., Cavdarli B., ARIK Z., Ozdal B., Ustun Y. E.  
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, cilt.18, sa.1, ss.84-92, 2022 (SCI-Expanded)
- IX. **Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment**  
GÜRLER F., İlhan A., GÜVEN D. C., TURHAN O., KURT İNCİ B., SÜTCÜOĞLU O., Yildiz F., ARIK Z., Oksuzoglu B., YALÇIN Ş., et al.  
ANTI-CANCER DRUGS, cilt.33, sa.1, 2022 (SCI-Expanded)
- X. **Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma**  
Gurler F., GÜVEN D. C., Aydemir E., SÜTCÜOĞLU O., İnci B. K., ARIK Z., YALÇIN Ş., ÖZDEMİR N., ÖZET A., YAZICI O.  
TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.52, sa.5, ss.1559-1568, 2022 (SCI-Expanded)
- XI. **Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality**  
GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇEŞMECİ E., Incesu F. G. G., TAHILLIOĞLU Y., ÜÇGÜL E., AKSUN M. S., GÜRBÜZ S. Ç., AKTEPE O. H., et al.  
BMJ SUPPORTIVE & PALLIATIVE CARE, 2021 (SCI-Expanded)
- XII. **Should Protocols Specific to Histologic Subtypes Be Applied in the Follow-Up of NSCLC?**  
ARIK Z., ERMAN M.  
JOURNAL OF THORACIC ONCOLOGY, cilt.16, sa.10, 2021 (SCI-Expanded)
- XIII. **Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy**  
GÜVEN D. C., AKSUN M. S., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., TABAN H., Ceylan F., KERTMEN N., ARIK Z.,

DİZDAR Ö., et al.

SUPPORTIVE CARE IN CANCER, cilt.29, sa.9, ss.5417-5423, 2021 (SCI-Expanded)

- XIV. **The prognostic significance of microsatellite status and its relationship with tumor-infiltrating lymphocyte in endometrial cancer**  
Lacin S., TAŞAR KAPAKLI G. E., USUBÜTÜN A., ARIK Z., YÜCE D., SALMAN M. C., Kars A.  
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, cilt.42, sa.3, ss.541-547, 2021 (SCI-Expanded)
- XV. **Multi-institutional validation of the ESMO-ESGO-ESTRO consensus conference risk grouping in Turkish endometrial cancer patients treated with comprehensive surgical staging**  
GÜLTEKİN M., Guler O. C., Sari S., Yildirim B. A., Onal C., Celik H., Yuce K., Ayhan A., ARIK Z., Kose F., et al.  
JOURNAL OF OBSTETRICS AND GYNAECOLOGY, cilt.41, sa.3, ss.414-420, 2021 (SCI-Expanded)
- XVI. **Perspectives, fears and expectations of patients with gynaecological cancers during the COVID-19 pandemic: A Pan-European study of the European Network of Gynaecological Cancer Advocacy Groups (ENGAGe)**  
GÜLTEKİN M., AK S., AYHAN A., Strojna A., Pletnev A., Fagotti A., Perrone A. M., ERZENEÖĞLU B. E., TEMİZ B. E., Lemley B., et al.  
CANCER MEDICINE, cilt.10, sa.1, ss.208-219, 2021 (SCI-Expanded)
- XVII. **Comparison of Efficacies of Dose Dense Paclitaxel Plus Carboplatin and Conventional Paclitaxel Plus Carboplatin in the Treatment of Epithelial Ovarian Cancer**  
Sunar V., Korkmaz V., Aslan K., Kose C., Sarici F., ARIK Z., Meydanli M. M.  
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, cilt.31, sa.4, ss.239-245, 2021 (SCI-Expanded)
- XVIII. **Defining the Optimal Regimen for Stage III Colon Cancer: Concerns with Study Design**  
GÜVEN D. C., GÜNER G., AKTAŞ B. Y., AKTEPE O. H., TABAN H., ARIK Z.  
CLINICAL COLORECTAL CANCER, cilt.19, sa.3, 2020 (SCI-Expanded)
- XIX. **Efficacy of Pazopanib in patients with metastatic uterine sarcoma: A multi-institutional study**  
Sunar V., Korkmaz V., AKIN S., GÜVEN D. C., ARIK Z., Ates O., Yilmaz M., Meydanli M. M., Oksuzoglu B.  
JOURNAL OF BUON, cilt.24, sa.6, ss.2327-2332, 2019 (SCI-Expanded)
- XX. **Retrospective Analysis of Gestational Trophoblastic Neoplasia: Single Center Experience**  
Sunar V., Korkmaz V., ARIK Z., Ozdal B., Engin Ustun Y.  
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, cilt.29, sa.3, ss.168-175, 2019 (SCI-Expanded)
- XXI. **Cytoreductive Surgery for Intestinal Cancer Patients Metastatic to Ovaries Presenting as Primary Ovarian Cancer**  
Arik Z., Oz M., DİZDAR Ö., YILDIRIM M. E., OZGU E., TERZIOGLU S. G., GUNGOR T.  
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, cilt.26, sa.2, ss.110-115, 2016 (SCI-Expanded)
- XXII. **A systemic late recurrence after the first operation in a patient diagnosed with early-stage breast cancer: the latest recurrence in the literature**  
Keskin O. D., KERTMEN N., Karakas Y., BABACAN T., ARIK Z., Altundag K., Gullu I.  
JOURNAL OF BUON, cilt.20, sa.1, ss.348, 2015 (SCI-Expanded)
- XXIII. **Molecular subtypes in patients with inflammatory breast cancer; A single center experience**  
KERTMEN N., BABACAN T., Keskin O., Solak M., Sarici F., AKIN S., ARIK Z., Aslan A., ATEŞ Ö., AKSOY S., et al.  
JOURNAL OF BUON, cilt.20, sa.1, ss.35-39, 2015 (SCI-Expanded)
- XXIV. **Evaluation of the effect of comorbidity on survival in pancreatic cancer by using "Charlson Comorbidity Index" and "Cumulative Illness Rating Scale"**  
Kos F. T., Yazici O., Civelek B., Seker M., ARIK Z., AKSOY S., Uncu D., Ozdemir N., Zengin N.  
WIENER KLINISCHE WOCHENSCHRIFT, cilt.126, ss.36-41, 2014 (SCI-Expanded)
- XXV. **Association between common risk factors and molecular subtypes in breast cancer patients**  
Turkoz F. P., Solak M., Petekkaya I., Keskin O., KERTMEN N., Sarici F., ARIK Z., BABACAN T., Ozisik Y., Altundag K.  
BREAST, cilt.22, sa.3, ss.344-350, 2013 (SCI-Expanded)
- XXVI. **Demographic and clinico-pathological characteristics of breast cancer patients with history of oral alendronate use**  
Sendur M. A. N., Aksoy S., Yaman S., Arik Z., Ozdemir N. Y., Zengin N., Altundag K.  
MEDICAL ONCOLOGY, cilt.29, sa.4, ss.2601-2605, 2012 (SCI-Expanded)

- XXVII. **Dermatomyositis complicated with a soft tissue sarcoma**  
Sendur M. A. N., Aksoy S., Yaman S., Arik Z., Kilinc L., Zengin N.  
RHEUMATOLOGY INTERNATIONAL, cilt.32, sa.10, ss.3329-3330, 2012 (SCI-Expanded)
- XXVIII. **Can all beta blockers improve the breast cancer survival?**  
Sendur M. A. N., Aksor S., Yaman S., Arik Z., Altundag K.  
BREAST, cilt.21, sa.1, ss.107-108, 2012 (SCI-Expanded)
- XXIX. **Is There an Association between Blood Group and Survival in Pancreatic Cancer?**  
Kos F. T., Civelek B., Seker M. M., ARIK Z., AKSOY S., Uncu D., Ozdemir N., Zengin N.  
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, cilt.13, sa.12, ss.6151-6153, 2012 (SCI-Expanded)
- XXX. **Breast Cancer in a Patient with Agnogenic Myeloid Metaplasia**  
ARIK Z., OZKAN C., Ozdemir E., ALTUNDAG K.  
SOUTHERN MEDICAL JOURNAL, cilt.103, sa.10, ss.1075-1076, 2010 (SCI-Expanded)

## **Diğer Dergilerde Yayınlanan Makaleler**

- I. **Frontline Management of Advanced Epithelial Ovarian Cancer: A Comprehensive Statement by the Africa Middle East Cancer Inter-group [AMCI]**  
Seoud M., Ladjeroud A., Jaafar H., Mokhtar M., Ozyilkan O., Alkhayyat S., Dawood S., ARIK Z., Azim H. A.  
Current Women's Health Reviews, cilt.20, sa.1, 2024 (ESCI)
- II. **Comparison of Neoadjuvant Chemotherapy Plus Interval Debulking Surgery and Primary Debulking Surgery in Patients with Stage III and IV Ovarian Carcinoma: A Multicenter Real Life Experience**  
Yilmaz M., Başak M., Özyükseler D. T., Yildirim M. E., ARIK Z., SALMAN M. C., GÜLTEKİN M., Akgör U., Kurt İnci B., Gürler F., et al.  
Turk Onkoloji Dergisi, cilt.38, sa.3, ss.323-332, 2023 (ESCI)
- III. **Leptomeningeal metastasis in primary uterine cervical cancer: a rare case and review of the literature**  
KAHVECİOĞLU A., Sari S. Y., YILDIRIM H. Ç., ARIK Z., GÜLTEKİN M., YILDIZ F.  
Corrosion Science and Technology, cilt.19, sa.3, ss.184-189, 2023 (ESCI)
- IV. **The impact of COVID-19 pandemic on nosocomial multidrug-resistant bacterial bloodstream infections and antibiotic consumption in a tertiary care hospital**  
Metan G., Cuha M. D., Hazirolan G., Dizman G. T., Tanriverdi E. S., Otlu B., TAŞ Z., Zarakolu P., Arik Z., Topeli A., et al.  
GMS HYGIENE AND INFECTION CONTROL, cilt.17, 2022 (ESCI)
- V. **Ovarian Carcinoma Presenting With a Large Cervical Mass**  
YILMAZ M. T., GÜRLEK E., GÜLTEKİN M., Kahraman K., SALMAN M. C., USUBÜTÜN A., AKATA D., ERGÜN E., ARIK Z., YILDIZ F.  
CUREUS JOURNAL OF MEDICAL SCIENCE, cilt.14, sa.1, 2022 (ESCI)

## **Kitap & Kitap Bölümleri**

- I. **Kastrasyona dirençli prostat kanseri tedavisi**  
ERMAN M., ARIK Z.  
Üroonkoloji Kitabı, , Editör, Nobel, 2018

## **Hakemli Kongre / Sempozyum Bildiri Kitaplarında Yer Alan Yayınlar**

- I. **Embedded outpatient palliative care service within the oncology clinic: Preliminary experience in Hacettepe Oncology Hospital**  
Güven D. C., AKTEPE O. H., Berk Z., Güner G., Taban H., AKTAŞ B. Y., Duran Z. C., AKIN Ş., ARIK Z., KERTMEN N., et al.

44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30

**II. Clinicopathologic features of BRCA mutated breast cancer patients: Hacettepe experience**

AKSOY S., DEĞİRMENCİLER R. F., AKTAŞ B. Y., Guven D. C., AKTEPE O. H., Guner G., Taban H., KERTMEN N., ARIK Z., DİZDAR Ö.

44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30

**III. Is microsatellite instability a negative prognostic factor in early stage endometrial cancer patients?**

Lacin S., Tasar G. E., Usubutun A., Arik Z., Karakas Y., Yuce D., Salman M. C., Kars A.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37

**IV. TRASTUZUMAB KARDİYOTOKSİSİTESİNİ İMMUNGLOBULİN /- STEROİD UYGULAMASI ÖNLEYEBİLİR Mİ?, TAVŞAN MODELİ HAYVAN DENEYİ**

KERTMEN N., AKSOY S., ERMİŞ D. Y., KESKİN Ö., SOLAK M., ARIK Z., SARICI F., ATEŞ Ö., ALTUNDAĞ M. K.

22. UKK, Türkiye, 19 - 23 Nisan 2017

**V. Cytoreductive surgery for intestinal cancer patients metastatic to the adnexal presenting as primary ovarian cancer.**

Arik Z., Dizdar O., Yildirim M. E., Ozgu E., Oz M., Terzioglu S. G., Gungor T.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33

**VI. Which sequence prevents the heart from trastuzumab and anthracycline toxicity: Electron microscopy study in rats**

Aksoy S., Kertmen N., ÜNER A., Sargon M., Ozkayar O., Keskin O., Babacan T., Sarici S. F., Sendur M. A. N., Arik Z., et al.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32

**VII. Temporal changes in the survival of metastatic renal cell cancer patients and the impact of targeted agents: Single center experience**

Erman M., Arik Z., Kilickap S., Bilen C. Y., Yazici S., Akdogan B., Ozen H.

Genitourinary Cancers Symposium, San-Francisco, Kostarika, 30 Ocak - 01 Şubat 2014, cilt.32

**VIII. Arrhythmias during and after zoledronic acid infusion patients with bone metastasis.**

Yazici O., Aksoy S., Ucar O., Ozdemir N., Demir M., Sendur M. A. N., Arik Z., Yaman S., Eren T., Uncu D., et al.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31

**IX. Clinicopathologic characteristics of pure papillary breast carcinoma**

Turkoz F. P., Solak M., Keskin O., Arik Z., Arslan C., Kertmen N., Aksoy S., Altundag K.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31

**X. Inflammatory markers in metastatic breast cancer.**

Sahin U., Petekkaya H., Gecmez G., Babacan T., Roach E. C., Sarici S. F., Arslan C., Arik Z., Aksoy S., Altundag K.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31

**XI. Variations of the ER, PR, and HER2 expression status according to operation day in breast cancer patients.**

Arik Z., Aksoy S., Sendur M. A. N., Yaman S., Altundag K.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30

**XII. Administration of contrast media just before the cisplatin-based chemotherapy increases the cisplatin-induced nephrotoxicity.**

Sendur M. A. N., Aksoy S., Yaman S., Kos F. T., Arik Z., Civelek B., Ozdemir N., Uncu D., Zengin N.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 -

06 Haziran 2012, cilt.30

**XIII. Does total breastfeeding time influence the clinicopathologic characteristics and prognosis in breast cancer patients?**

Yaman S., Aksoy S., Sendur M. A. N., Arik Z., Ozdemir N., Zengin N., Altundag K.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 -

06 Haziran 2012, cilt.30

**XIV. Demographic and clinicopathologic characteristics of breast cancer patients with history of oral alendronate use**

Aksoy S., Sendur M. A. N., Yaman S., Arik Z., Ozdemir N., Zengin N., Altundag K.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 -

06 Haziran 2012, cilt.30

## **Metrikler**

Yayın: 51

Atıf (WoS): 127

Atıf (Scopus): 115

H-İndeks (WoS): 5

H-İndeks (Scopus): 6

## **Akademi Dışı Deneyim**

SAĞLIK BAKANLIĞI ESKİŞEHİR YUNUS EMRE DEVLET HASTANESİ

Zekai Tahir Burak Kadın Sağlığı Eğitim ve Araştırma Hastanesi